# Plasma Proteomic Dynamics Preceding Glaucoma Reveal a 15-Year Pre-Diagnostic Window: Causal Insights and Predictive Utility in 45,850 Participants

**Authors:** Yingke Zhao, Jiawen Wu, Chenchen Li, Yun Cheng, Qian Li, Jianing Wu, Zhongmou Sun, Shenghai Zhang, Jihong Wu

PMC · DOI: 10.1167/iovs.67.3.14 · 2026-03-06

## TL;DR

This study shows that changes in blood proteins can be detected up to 15 years before glaucoma diagnosis, offering early detection and potential treatment targets.

## Contribution

The study identifies a 15-year pre-diagnostic window for glaucoma using plasma proteomics and causal proteins like LTBP2.

## Key findings

- 136 proteins were significantly associated with glaucoma risk, with EDA2R showing the strongest link.
- Four causal proteins were identified, implicating extracellular matrix and immune processes in glaucoma.
- Predictive models using proteomic signatures improved two-year prediction accuracy by 14.65% over demographics.

## Abstract

To characterize the temporal dynamics of plasma proteomic changes preceding glaucoma diagnosis, identify causal proteins, and evaluate their predictive utility for early detection.

We conducted a prospective cohort study of 45,850 UK Biobank participants without baseline glaucoma, followed for a median of 16.26 years. Plasma levels of 2920 proteins were measured using the Olink Explore 3072 platform. Cox proportional hazards models identified proteins associated with incident glaucoma. Mendelian randomization (MR) using cis- protein quantitative trait loci established causal relationships. Temporal trajectories were modeled using LOESS regression, and time-stratified machine learning models were developed to assess predictive performance.

During follow-up, 977 incident glaucoma cases were identified. After comprehensive adjustment, 136 proteins were significantly associated with glaucoma risk (false discovery rate < 0.05), with EDA2R showing the strongest association (hazard ratio [HR] = 1.21, 95% confidence interval [CI] = 1.16–1.25, P = 2.99 × 10−17). MR analysis identified four causal proteins: LTBP2 (odds ratio [OR] = 1.52, 95% CI = 1.36–1.71, P = 1.07 × 10−12), NRP2 (OR = 0.85, 95% CI = 0.78-0.92, P = 4.73 × 10−5), TNFSF13, and HAVCR1—implicating extracellular matrix remodeling and immune dysregulation in disease pathogenesis. Proteomic dysregulation commenced 12 to 15 years before clinical diagnosis, with three distinct temporal patterns identified. Time-stratified predictive models incorporating these signatures achieved an area under the curve of 0.803 (95% CI = 0.772-0.837) for up to two-year prediction, a 14.65% improvement over demographic models.

This study reveals a 15-year window of detectable plasma proteomic dysregulation preceding glaucoma diagnosis. The identified causal proteins, particularly LTBP2, provide mechanistic insights and represent potential therapeutic targets. The strong predictive performance demonstrates the translational potential of these findings for risk-stratified screening.

## Linked entities

- **Proteins:** EDA2R (ectodysplasin A2 receptor), LTBP2 (latent transforming growth factor beta binding protein 2), NRP2 (neuropilin 2), TNFSF13 (TNF superfamily member 13), HAVCR1 (hepatitis A virus cellular receptor 1)
- **Diseases:** glaucoma (MONDO:0005041)

## Full-text entities

- **Genes:** MMP12 (matrix metallopeptidase 12) [NCBI Gene 4321] {aka HME, ME, MME, MMP-12}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, APOA4 (apolipoprotein A4) [NCBI Gene 337] {aka ADTKD6}, PI3 (peptidase inhibitor 3) [NCBI Gene 5266] {aka ESI, SKALP, WAP3, WFDC14, cementoin}, GUCA2A (guanylate cyclase activator 2A) [NCBI Gene 2980] {aka GCAP-I, GUCA2, STARA}, OPTC (opticin) [NCBI Gene 26254] {aka OPT}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, LAMTOR5 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 5) [NCBI Gene 10542] {aka HBXIP, XIP}, NFASC (neurofascin) [NCBI Gene 23114] {aka NEDCPMD, NF, NRCAML}, CTSO (cathepsin O) [NCBI Gene 1519] {aka CTSO1}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319] {aka SL-2, STMY2}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, GALNT10 (polypeptide N-acetylgalactosaminyltransferase 10) [NCBI Gene 55568] {aka GALNACT10, PPGALNACT10, PPGANTASE10}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, LTBP2 (latent transforming growth factor beta binding protein 2) [NCBI Gene 4053] {aka C14orf141, GLC3D, LTBP3, MSPKA, MSTP031, WMS3}, EPHA2 (EPH receptor A2) [NCBI Gene 1969] {aka ARCC2, CTPA, CTPP1, CTRCT6, ECK}, EDA2R (ectodysplasin A2 receptor) [NCBI Gene 60401] {aka EDA-A2R, EDAA2R, TNFRSF27, XEDAR}, TNFSF13 (TNF superfamily member 13) [NCBI Gene 8741] {aka APRIL, CD256, TALL-2, TALL2, TNLG7B, TRDL-1}, HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762] {aka CD365, HAVCR, HAVCR-1, KIM-1, KIM1, TIM}, PLA2G10 (phospholipase A2 group X) [NCBI Gene 8399] {aka GXPLA2, GXSPLA2, SPLA2, sPLA2-X}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, NRP2 (neuropilin 2) [NCBI Gene 8828] {aka NP2, NPN2, PRO2714, VEGF165R2}, PRCP (prolylcarboxypeptidase) [NCBI Gene 5547] {aka HUMPCP, PCP}, TGFBR2 (transforming growth factor beta receptor 2) [NCBI Gene 7048] {aka AAT3, FAA3, LDS1B, LDS2, LDS2B, MFS2}, CRELD1 (CRELD disulfide isomerase 1) [NCBI Gene 78987] {aka AVSD2, CIRRIN, JELANS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PTPRB (protein tyrosine phosphatase receptor type B) [NCBI Gene 5787] {aka HPTP-BETA, HPTPB, PTPB, R-PTP-BETA, VEPTP}, SCARB2 (scavenger receptor class B member 2) [NCBI Gene 950] {aka AMRF, CD36L2, EPM4, HLGP85, LGP85, LIMP-2}, TNFSF13B (TNF superfamily member 13b) [NCBI Gene 10673] {aka BAFF, BLYS, CD257, TALL-1, TALL1, THANK}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}
- **Diseases:** Glaucoma (MESH:D005901), nervous and respiratory system diseases (MESH:D015619), immune dysregulation (OMIM:614878), diseases of the urinary system (MESH:D014570), axonal dysfunction (MESH:D001480), ocular infections (MESH:D015817), death (MESH:D003643), hypertension (MESH:D006973), POAG (MESH:D005902), blindness (MESH:D001766), Inflammation (MESH:D007249), neurodegeneration (MESH:D019636), familial glaucoma (MESH:C580055), optic nerve damage (MESH:D020221), fibrosis (MESH:D005355), optic neuropathy (MESH:D009901), loss of peripheral vision (MESH:D014786), VF (MESH:C537182), tumors (MESH:D009369), field loss (MESH:D007922)
- **Chemicals:** alcohol (MESH:D000438), Belimumab (MESH:C511911), EDTA (MESH:D004492)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12974536/full.md

---
Source: https://tomesphere.com/paper/PMC12974536